Bank Julius Baer & Co. Ltd, Zurich Fibrogen Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$12.02 - $16.79 $31,252 - $43,654	-2,600 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $91 - $239	9 Added 0.35%	2,600 $27,000
Q2 2021 Jul 23, 2021	BUY	$18.57 - $35.68 $21,949 - $42,173	1,182 Added 83.89%	2,591 $69,000
Q1 2021 May 10, 2021	SELL	$31.0 - $55.72 $204,569 - $367,696	-6,599 Reduced 82.41%	1,409 $49,000
Q4 2020 Feb 24, 2021	BUY	$37.09 - $48.97 $296 - $391	8 Added 0.1%	8,008 $297,000
Q3 2020 Nov 10, 2020	SELL	$40.47 - $45.5 $4,694 - $5,278	-116 Reduced 1.43%	8,000 $329,000
Q1 2020 May 13, 2020	BUY	$23.3 - $45.96 $189,102 - $373,011	8,116 New	8,116 $281,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.